Trial Profile

Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Letetresgene autoleucel (Primary) ; MAGE A3 6 specific t cells (Primary)
Indications Malignant melanoma
Focus Adverse reactions
Sponsors Adaptimmune

Most Recent Events

07 May 2018 Status changed from active, no longer recruiting to discontinued due to lack of enrollement.
13 Mar 2017 Planned primary completion date changed from 1 May 2021 to 1 May 2018.
07 Dec 2016 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com